Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Licensing Due Diligence

Related Content

Healthcare M&A and Financing Trends and Predictions for 2024

European Commission’s First-Ever Abuse of Dominance Probe for Shelving of a Novel Pipeline Therapy

Delaware Supreme Court Holds That Boards Must Satisfy the MFW Framework in Controller Transactions to Obtain Business Judgment Deference

SEC Adopts Reforms Relating to Investment Advisers Operating Exclusively Through the Internet

At the Intersection of ‘S’ and ‘G’ of ESG: London Leading the Way on Board Diversity — An Update on Latest FTSE Women Leaders Review and Parker Review Reports

Agencies Extend Applicability Date of Certain Provisions of their CRA Final Rule

FinCEN Publishes an Administrative Ruling Regarding Customer Identification Program and Customer Due Diligence Requirements for Designated Beneficiaries of Individual Retirement Accounts

Federal Reserve Announces Final Rule Updating Risk Management Requirements for Certain Systemically Important Financial Market Utilities

What Tech Companies Need to Know: State of Tech M&A Panel

Digital Markets Guide: US Skepticism of Tech Transactions Sparks a Step-Up in Merger Enforcement (GCR)

Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion

Auradine Raises $80 Million in Series B Financing and Achieves $80 Million in Bookings

Deal Watch: M&A (Law.com)

US Law Firms Ride Rising M&A Wave in Q1 (Reuters)

Q1 PE League Tables: Making it Private (The Deal)

AlmataBio Acquired by Avalo Therapeutics For $22.5 Million

Life Sciences

Mergers & Acquisitions